Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 12/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31129674 | 0.99 | IKZF2 (0.48) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL31129642 | 0.98 | IKZF2 (0.48) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL25133940 | 0.96 | IKZF2 (0.50) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL29927821 | 0.96 | IKZF2 (0.50) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL29132146 | 0.96 | IKZF2 (0.50) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL31129343 | 0.96 | IKZF2 (0.48) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL31129506 | 0.96 | IKZF2 (0.48) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL31129378 | 0.94 | IKZF2 (0.49) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL31129693 | 0.92 | IKZF2 (0.46) | IKZF2IKZF1CRBNIKZF3DDB1 | |
| SCHEMBL27270975 | 0.91 | IKZF2 (0.50) | IKZF2IKZF1CRBNIKZF3DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | ARVINAS OPERATIONS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2024159164-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | CRBN, KRAS, WEE1 | IKZF2 438/4885IKZF1 737/4885CRBN 1/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | IKZF2 499/4885IKZF1 435/4885CRBN 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.